Condor Research, operated by Atrio Sciences s.r.o. in Slovakia, supplies reference compounds that are tested by an independent third-party laboratory in the EU before they are offered, and each batch ships with a lot-specific Certificate of Analysis (COA). This page explains what a COA is, what the testing actually measures, and how to read one critically — without inventing numbers we cannot stand behind. All materials are supplied strictly for research use only (RUO) and in vitro investigation. Nothing here describes or implies suitability for human or veterinary use.
What does “COA-tested” actually mean here?
“COA-tested” is one of the most over-used phrases in the research-compound market, so it is worth being exact. At Condor it means a specific, verifiable chain: every batch is analysed by an independent third-party laboratory based in the EU (located in Czechia) before it is listed, and the results of that analysis are issued as a Certificate of Analysis tied to that specific lot number. We do not rely solely on supplier-provided paperwork or on internal testing. The COA is not a marketing graphic or a generic product sheet — it is the lab’s report on the exact material you receive.
The distinction matters because the meaningful question is never simply “is there a purity number?” It is who generated that number, by what method, and for which batch? A figure printed on a website with no traceable source is a claim. A figure on a lot-specific COA from a named independent laboratory is a data point a researcher can actually use.5
What is a Certificate of Analysis?
A COA is a structured laboratory report documenting how one batch of material performed against a defined set of specifications. The international vocabulary for this comes from the ICH Q6A framework, which defines a specification as a list of tests, references to analytical procedures, and acceptance criteria the material must meet to be deemed acceptable.1 In plain terms, a COA answers a fixed set of questions for a fixed batch: what is the substance, what tests were run, what method was used for each, what was the acceptance criterion, what was the result, and which lot does this describe.
For a deeper, section-by-section walkthrough of these documents, see our guide on how to read a Certificate of Analysis. For the specific question of what a purity percentage does and does not prove, see what “99% pure” on a peptide COA really means.
What does the testing measure?
Two questions sit at the centre of any peptide COA, and they are not the same: identity (is this the right molecule?) and purity (how much of the sample is that molecule?). A batch can be highly pure and still be the wrong compound, which is why the two are tested separately.4 The core analytical methods are described in general terms below — we report what is measured, not invented lot figures.
| What is measured | Method | What it establishes | Scope / specification |
|---|---|---|---|
| Independent testing | Third-party EU laboratory (Czechia) | Results are not self-reported by the seller or relied on solely from the supplier | Every batch |
| Identity | HPLC; mass spectrometry (MS) for peptides | Confirms the material is the stated compound; MS weighs the molecule against its theoretical mass | All compounds; MS adds mass confirmation for peptides |
| Purity | HPLC (high-performance liquid chromatography) | Quantifies how much of the material is the target compound versus related impurities | ≥99% for individual compounds; per-component for blends |
| Hazard documentation | SDS / CLP under REACH | Provides classification, labelling and safe-handling information for the lab | Where applicable |
| Traceability | Per-batch COA with lot number | Links the analytical data to the exact lot you receive | Every batch |
Impurity control is its own discipline: the ICH Q3A framework treats the identification and limitation of impurities as a separate problem from the purity number itself,2 and chromatographic purity is method-dependent — the figure reflects the laboratory’s HPLC conditions, as the USP general chapter on chromatography sets out.3 The EMA’s guideline on the development and manufacture of synthetic peptides asks manufacturers to demonstrate exactly this combination of confirmed identity and a characterised impurity profile.5
What does a Condor COA include?
A Condor COA is lot-specific and reflects the third-party testing above. It typically documents the compound identity (HPLC, plus mass spectrometry for peptides), the purity result from HPLC against the ≥99% specification for individual compounds (or per component for blends), mass-spectrometry confirmation for peptides, and the batch / lot number for traceability. Because the certificate is tied to a lot, it is the document a researcher should retain for record-keeping and method validation — not a generic datasheet. Where REACH applies, a separate Safety Data Sheet covers hazard classification and handling.
We do not publish invented purity figures, lot numbers, or laboratory names on this page. The actual numbers live on the certificate that accompanies each batch. Lot-specific certificates will be collected in our COA database, so the document for a given lot can be located and retained.
Why does independent, third-party testing matter?
This is not regulatory theatre. A large share of irreproducible preclinical research has been traced to flawed or mis-identified biological reagents and reference materials — when you cannot say with evidence what was in the tube, downstream results cannot be trusted or compared between labs.6 An independently generated, lot-specific COA is the most direct defence against that failure mode. It is what lets a researcher treat a reported purity and identity as verifiable analytical results rather than a hopeful label.
We state the limits plainly to avoid overclaiming. A ≥99% HPLC purity specification describes the chromatographic purity of the target compound for that lot under the laboratory’s method; it is an analytical characterisation for laboratory research, not a statement about safety, efficacy, or any use in humans or animals.5 For blends, purity is reported per component rather than as one aggregate figure that could mask a weaker constituent. SDS/CLP documentation is provided where applicable under REACH, not as a blanket claim across every item. For the full quality program and its boundaries, see Quality & Third-Party Testing.
Buyer checklist: judging any “tested” claim
Whether you are evaluating Condor or any other supplier, this checklist helps you judge what a certificate actually demonstrates:
- ☐ Is the testing independent? Look for a named third-party laboratory rather than seller-only or supplier-only data. Condor uses an independent EU lab in Czechia.
- ☐ Is the COA lot-specific? A batch / lot number should tie the data to the exact material. Condor issues a COA per batch.
- ☐ What method produced the purity figure? HPLC is the expected method for purity; Condor specifies ≥99% for individual compounds.
- ☐ For blends, is purity reported per component? A single aggregate number can hide a weak constituent. Condor reports per component.
- ☐ For peptides, is identity confirmed by MS? Mass spectrometry confirms the molecule matches its expected mass. Condor applies MS to peptides.
- ☐ Is hazard documentation available? An SDS with CLP classification under REACH should be provided where applicable.
Explore COA-tested compounds
The same third-party testing process applies across the catalog. A selection of flagship compounds:
- BPC-157 — the most-referenced repair peptide; see the primer What is BPC-157?
- TB-500 — full-length thymosin β4; compared in BPC-157 vs TB-500.
- GHK-Cu — the copper-binding tripeptide; background in What is GHK-Cu?
- GLOW (GHK-Cu + BPC-157 + TB-500) — a blend where purity is reported per component.
- Semax and Epitalon — research-grade nootropic and bioregulator peptides.
- NAD+ and NMN Capsules — NAD-metabolism research materials in vial and capsule formats.
All products supplied by Condor Research (Atrio Sciences s.r.o.) are for research use only / in vitro use. They are not for human or veterinary use, not drugs, foods, or cosmetics, and not for diagnostic or therapeutic purposes.
Frequently asked questions
What does “COA-tested” mean at Condor Research?
It means every batch is analysed by an independent third-party laboratory in the EU (Czechia) before listing, and the results are issued as a Certificate of Analysis tied to that specific lot number. Testing is not relied upon solely from the supplier or done only in-house.
What does a Condor COA measure?
Identity (HPLC, plus mass spectrometry for peptides) and purity (HPLC, with a ≥99% specification for individual compounds and per-component reporting for blends). The certificate also carries the batch/lot number for traceability. Where REACH applies, a separate SDS covers hazard classification.
Can I see the COA for the exact lot I receive?
Yes. The COA is lot-specific, so it corresponds to the batch you receive rather than a generic product sheet. Lot-specific certificates are being collected in our COA database.
Is the testing independent or in-house?
It is performed by an independent third-party laboratory based in the EU (Czechia), not solely in-house or relied on only from the supplier. That independence is what lets researchers treat the reported purity and identity as verifiable analytical results.
What purity standard is used?
≥99% by HPLC for individual compounds; for blends, purity is reported per component rather than as a single aggregate figure. This is an analytical measurement for research use only and does not speak to safety, efficacy, or any human or veterinary use.
Why does third-party COA testing matter for research?
Reproducible science depends on knowing exactly what is in the vial. A substantial share of irreproducible preclinical work has been linked to flawed or mis-identified reagents and reference materials, so an independent, lot-specific COA is the most direct way to make a result trustworthy and comparable between laboratories.
Condor Research · Scientific desk
- International Council for Harmonisation. ICH Q6A: Specifications — Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products. https://www.ich.org/page/quality-guidelines
- International Council for Harmonisation. ICH Q3A(R2): Impurities in New Drug Substances. https://www.ich.org/page/quality-guidelines
- United States Pharmacopeia. General Chapter <621> Chromatography. USP-NF. https://www.usp.org/harmonization-standards/dsc
- Fosgerau K, Hoffmann T. Peptide therapeutics: current status and future directions. Drug Discov Today. 2015. PMID: 25450771. doi:10.1016/j.drudis.2014.10.003. https://pubmed.ncbi.nlm.nih.gov/25450771/
- European Medicines Agency. Guideline on the development and manufacture of synthetic peptides. https://www.ema.europa.eu/en/development-manufacture-synthetic-peptides-scientific-guideline
- Freedman LP, Cockburn IM, Simcoe TS. The Economics of Reproducibility in Preclinical Research. PLoS Biol. 2015. PMID: 26057340. doi:10.1371/journal.pbio.1002165. https://pubmed.ncbi.nlm.nih.gov/26057340/